Loss of synapses, or communication-conveying connections between one nerve cell and another, does not explain the early cognitive impairment in Alzheimer’s patients, researchers concluded. The study, “Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer’s disease at various cognitive stages,” appeared in the…
A novel strategy using healthy plasma infusions led to promising results in patients with mild to moderate Alzheimer’s disease, Alkahest recently announced. Stanford Medicine presented clinical data of its PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (NCT02256306) Nov. 4 at the 10th Clinical Trials on Alzheimer’s Disease conference in…
M3 Biotechnology will test a regenerative therapy for Alzheimer’s in a Phase 1 clinical trial. The Seattle-based company designed NDX-1017 to slow or stop the progression of the disease, and perhaps reverse it, by restoring lost nerve cell connections in the brain. “Current drugs on the market for Alzheimer’s patients offer…
University of Maryland students have developed a device to diagnose Alzheimer’s before its symptoms are evident. It uses sounds to detect changes in the brainwaves of people with the disease. The achievement earned the seven team members — all sophomores at the A. James Clark School of Engineering — the top prize at…
The first participant in a Phase 1 clinical trial of HTL0016878 as a treatment for cognitive impairment in Alzheimer’s disease is receiving the therapy, according to its developer, Heptares Therapeutics. Heptares, a subsidiary of Japan’s Sosei Group Corporation, and Ireland-based Allergan are partnering in the trial under a treatment development and…
The link between brain inflammation, cell growth and division, and neuronal death could provide a target to treat Alzheimer’s and other neurodegenerative disease, research suggests. The study, “LPS-induced inflammatory response triggers cell cycle reactivation in murine neuronal cells through retinoblastoma proteins induction,” appeared in the journal Cell Cycle. The…
Odor identification tests may help track Alzheimer’s disease (AD) in persons at risk even before the onset of symptoms, a new study shows. The study, “Odor identification as a biomarker of preclinical AD in older adults at risk,” appeared in the journal Neurology. Gradual memory loss is observed…
New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer’s Association International Conference (AAIC) in London July 16-20. Intepirdine is a selective antagonist of the…
Researchers have discovered a common link between abnormal proteins that cause damage to brain cells in Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s (HD) disease patients. The discovery could help scientists understand the mechanism by which these neurodegenerative diseases spread, and possibly lead to a therapy…
A new DNA vaccine protects against accumulation of toxic proteins in Alzheimer’s disease, according to new research. One study, “Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer,” appeared in the Journal of Alzheimer’s…
Get regular updates to your inbox.